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The significance of selegiline/(− )-deprenyl after 50 years in
research and therapy (1965–2015)
I Miklya
Deprenyl/Selegiline (DEP), created by Joseph Knoll in the 1960s, registered in more than 60 countries to treat Parkinson’s disease,
Alzheimer’s disease, major depressive disorder; and used as an anti-aging drug, achieved its place in research and therapy as the
first selective inhibitor of B-type monoamine oxidase (MAO-B). The demonstration that the DEP analog (− )-1-phenyl-2-
propylaminopentane devoid of MAO inhibitory property, enhanced like DEP the activity of the catecholaminergic brain engine
revealed that this effect is unrelated to the selective inhibition of MAO-B. β-Phenylethylamine (PEA), the important trace-amine in
the mammalian brain, is known to be a releaser of catecholamines. Amphetamine and methamphetamine, the best known
synthetic PEA derivatives are also releasers of catecholamines like their parent compound. DEP is a unique synthetic PEA derivative
devoid of the catecholamine releasing property. As the releasing effect conceals the catecholaminergic activity enhancer (CAE)
effect, it remained undiscovered until DEP uncovered that PEA is a natural CAE substance; and only releases catecholamines in high
concentration. Discovering that tryptamine is a natural enhancer of catecholaminergic and serotonergic neurons catalyzed the
development of R-(− )-1-(benzofuran-2-yl)-2-propylaminopentane (BPAP); the most potent and selective enhancer substance, and it
exerts its enhancer effect in 0.0001 mg kg−1. DEP and BPAP initiated an analysis of the enhancer regulation in the mammalian
brain. Studies regarding the nature of the enhancer regulation revealed that this regulation is enhanced after weaning and sex
hormones return it to the pre-weaning level. Thus, sex hormones elicit the transition of the developmental phase of life into the
post-developmental, downhill (aging) period. The aging-related, slow decline in the enhancer regulation of the catecholaminergic
brain engine, the main activator of the cortex, is the prime factor of brain aging. The enhancer regulation’s decay in the most
rapidly aging dopaminergic system is, for example, mainly responsible for the decline in learning ability and sexual activity over
time. According to the Knoll concept, based on two longevity studies performed on male rats, to keep the catecholaminergic brain
engine, from the beginning of the downhill period of life, via the administration of a small daily dose of a CAE substance (presently
DEP is the only available drug) on a higher activity level, thus to fight against the physiological aging-related slow decay of the
catecholaminergic system, is a suitable anti-aging therapy. As our present knowledge regarding the enhancer regulation in the
mammalian brain is like seeing a peak of an iceberg, the future of this new line of brain research looks promising from both
theoretical and practical aspects.
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DEVELOPMENT OF DEPRENYL
Knoll started in the early 1950s behavioral studies on rats and
realized the extraordinary importance of the catecholaminergic
brain machinery (the engine of the brain) in the fixation of
acquired drives. To stimulate the brain engine he used
amphetamines, releasers of catecholamines, which unforeseeably
disturb purposeful behavior. To avoid this side effect he designed
and performed a structure–activity relationship study and selected
E-250, later named deprenyl, for detailed analysis. The first
publication in English appeared in 1965 and the (− )-enantiomer,
(R)-N-methyl-N-(1-phenylpropan-2-yl)-prop-1-yn-3-amine [Selegi-
line, (− )-Deprenyl (DEP)] was developed.1
THE UNIQUE MAOI DEVOID OF THE ‘CHEESE EFFECT’
Knoll designed E-250 as a new antidepressant. Both ( ± )-E-2502
and (− )-E-2503 (DEP) were shown by Varga to be prompt acting
antidepressants. The finding was first confirmed by Mann and
Gershon4 and later in numerous papers. In 2002 Bodkin and
Amsterdam published their first clinical trial with a new DEP
preparation, the selegiline-transdermal system (STS).5 In 2006 the
FDA approved STS (Emsam) for depression.
THE FIRST SELECTIVE INHIBITOR OF MAO-B
In 1963, in Lancet, a calamitous number of clinical reports gave
accounts of patients treated with monoamine oxidase inhibitors
(MAOIs) that temporarily developed hypertensive crises. Blackwell
suggested that the symptoms are associated with the ingestion of
high amounts of tyramine in cheese, the metabolism of which is
inhibited by the MAOIs (‘cheese effect’).6 This side effect restricted
their clinical use. Knoll’s discovery that DEP is a unique MAOI
free of the ‘cheese effect’;7 and this was verified in 1978 in
human studies;8,9 was of notable therapeutic importance. DEP’s
safety made it possible to combine levodopa+DEP in Parkinson’s
disease (PD).10
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Knoll presented in 1971 at the First International MAO
Symposium that DEP is a selective inhibitor of B-type MAO
(MAO-B).11 The paper has become a citation classic, and DEP is still
a key important experimental tool in MAO research.
FIRST CLINICAL TRIAL OF DEP IN PD
Because of the serious side effects of levodopa in PD, Birkmayer
and Hornykiewicz attempted to achieve a levodopa-sparing effect
with the concurrent administration of levodopa with an MAO
inhibitor, but the frequently elicited hypertensive attacks termi-
nated this trial.12 Birkmayer combined first DEP with levodopa and
achieved a levodopa-sparing effect without signs of hypertensive
reactions.10 This study and a Lancet Editorial (25 September 1982)
initiated the world-wide use of DEP in PD.
FIRST PROOF OF THE NEUROPROTECTIVE EFFECT OF DEP
It was first shown by Knoll and his coworkers13 in the late 1970s
that DEP treatment protects the dopaminergic neurons from the
toxic effect of the specific dopaminergic neurotoxin, 6-hydroxy-
dopamine (6-OHDA). DEP protects the striatum from the toxic
effects of 6-OHDA via the blockade of B-type MAO, the inhibition
of 6-OHDA uptake into the neuron, the facilitation of scavenger
function, and improved removal of neurotoxic free radicals.14
These conclusions catalyzed the discovery that DEP is significantly
enhancing the activity of superoxide dismutase in the striatum.15
Further studies revealed that DEP protects neurons against a
variety of neurotoxic agents: 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine; DSP-4; 5,6-dihyroxyserotonin; AF64A; increases pro-
duction of neurotrophins (nerve growth factor, brain-derived
neurotrophic factor and glial cell-derived neurotrophic factor)
which are natural protective agents of neurons; has an immunos-
timulant effect; increases interleukin (IL-2) and natural killer cell
activity; inhibits tumor growth, serum prolactin and suppresses
brain monoamine metabolism in rats with carcinogen-induced
mammary tumors; and is associated with enhanced central and
peripheral neurotransmission and immune activity.
CONCEPTUAL DEVELOPMENT THAT MAINTENANCE ON DEP
IMPROVES THE QUALITY OF LIFE IN THE LATTER DECADES
In 1981, Knoll defined his hypothesis that a progressively
developing catecholaminergic and trace-aminergic deficiency is
responsible for the biochemical lesion in the aging brain which
leads to the age-related decline in sexual and learning perfor-
mances and ultimately natural death,16 and soon proved that this
effect of DEP is unrelated to the inhibition of MAO-B.17
We lose 13% of our brain dopamine in the decade after
age 45.18 It is well established that during post-developmental
longevity there is also a continuously increasing PEA deficit in the
mammalian brain. As a rule, enzyme functions decrease in the
brain with the passing of time. MAO-B is an exception; its activity
is progressively increasing in the aging human brain.19 Also, the
activity of tyrosine hydroxylase, the enzyme catalyzing the rate-
limiting step in catecholamine biosynthesis, decreased in human
brain tissue with increasing age.20
FIRST TRIAL TO TEST THE REALITY OF HIS CONCEPT
Knoll proposed to Birkmayer, at that time the only clinician who
treated hundreds of his patients with Madopar+DEP, to analyze
the influence of DEP treatment on the survival of his patients. In
an open, uncontrolled study, the long term (9 years) effect of
treatment with Madopar alone (n= 377) or in combination with
DEP (n = 564) was compared in parkinsonian patients. The survival
analysis revealed a significant increase in the life expectancy of
the Madopar+DEP group regardless of the demographic differ-
ences between the groups.21
FIRST LONGEVITY STUDY WITH DEP
The study was performed on 2-year old, long living, robust,
Wistar–Logan male rats. Rats were treated three times a week
subcutaneously with saline (0.1 ml per 100 g) and DEP
(0.25 mg kg−1), respectively, until they died. As a measure of
striatal function, sexual activity was tested once a week in a group
of rats (n= 132) from the 24th month of their life. Due to aging-
related decay, none of the 2-year-old animals displayed full scale
sexual activity (mounting, intromission and ejaculation).
DEP treatment restored full scale sexual activity in 64 out of 66
rats. The first longevity study with DEP furnished unequivocal
experimental evidence that prophylactic DEP treatment signifi-
cantly prolongs the life of rats.15,22
The discovery that DEP treatment is significantly enhancing
scavenger function in the striatum of rats,15 but leaves superoxide
dismutase activity in the cerebellum unchanged23 signals the
specific CAE effect of DEP. This finding was corroborated in 1991
(ref. 24) and studied later in detail.
Knoll outlined the hypothesis that, as the activity of the
catecholaminergic system can be improved at any time during life,
it must essentially be feasible to develop a technique for
transforming a lower-performing, shorter-living individual, to a
better-performing, longer-living one. It, therefore, demonstrates
that a shift in the duration of life beyond the technical life span,
with a yet unpredictable upper limit, must be possible in all
mammals, including the human race.25
SECOND LONGEVITY STUDY WITH DEP
The aim of this study was to test how DEP treatment transforms a
lower-performing, shorter-living rat to a better-performing, longer-
living one. Out of 1600 sexually experienced male rats, the 94
sexually inactive (low performing) and the 99 most sexually active
(high performing, HP) rats were selected. The rats were treated
from the eigth month of life three times a week, subcutaneously,
with saline (0.1 ml per 100 g) and DEP (0.25 mg kg− 1), respec-
tively, until they died. Their copulatory activity was tested once
a week, and their learning performance was measured in the
shuttle box once every three months.
The saline-treated low-performing rats never displayed ejacula-
tion during their lifetime, and they were extremely low performers
in the shuttle box. Their DEP-treated peers became sexually active.
Their mating performance was substantially increased and lived
significantly longer than their salt-treated peers and as long of
time as the salt-treated HP rats. The salt-treated HP rats were
sexually active, and their learning performance was high. The
DEP-treated HP rats were much more sexually active than their
salt-treated peers. Also, their learning performance substantially
increased. They lived significantly longer than their salt-treated
peers. Out of 50 rats, 17 lived longer than the maximum life span
observed in the strain used in the study.26
The finding that DEP treatment prolongs life was confirmed
by rats; mice; Syrian hamsters; beagle dogs; and even Drosophila
melanogaster.
PROOF THAT DEP TREATMENT DELAYED THE NEED FOR
LEVODOPA THERAPY
Tetrud and Langston27 published first that a double-blind,
placebo-controlled study on 54 patients with early PD, randomly
assigned to DEP (10 mg per day) or placebo treatment groups and
followed until levodopa therapy was indicated, showed that the
average time until levodopa was needed was 312.1 days for
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patients in the placebo group and 548.9 days for patients in the
DEP group.
The DATATOP multicenter clinical trial that spanned 23
Universities in the USA and Canada, studied the ability of DEP
and α-tocopherol, antioxidant agents that act through comple-
mentary mechanisms. Eight hundred patients were randomly
assigned to a two-by-two factorial design to receive DEP,
α-tocopherol, a combination of both drugs, or placebo, and
were followed up to determine the frequency of development to
the end point. Due to the continuous deterioration of the
nigrostriatal dopaminergic neurons in PD, usually within one year
after diagnosis of the disease, patients need dopamine substitu-
tion (levodopa therapy). DEP treatment significantly delayed the
need for levodopa. By the end of the trial, 57% of patients who
received DEP did not need levodopa treatment, and these
patients also had a significant reduction in having to give up
full time employment. In contrast, α-tocopherol was ineffective.28
French, Swedish and Norwegian-Danish multicenter studies
confirmed this unique beneficial effect of DEP treatment in
de novo PD.
Since the mid-1980s, more and more convincing experimental
data indicated that the enhancement in the activity of the
catecholaminergic brain engine with DEP treatment is unrelated
to the selective inhibition of B-type MAO.29,30,31 The ineffective-
ness of α-tocopherol in the DATATOP study was in harmony with
this approach, which was later validated: DEP is enhancing the
impulse propagation-mediated release of dopamine (catechola-
minergic activity enhancer (CAE) effect), α-tocopherol is devoid of
this property,32 proving that the CAE effect was responsible for
the effectiveness of DEP in the DATATOP study.33 The clinical
trial performed by the Parkinson Study Group with rasagiline,
a selective inhibitor of MAO-B, revealed that unlike the early
selegiline trials, rasagiline, also devoid of the CAE effect,34 did not
decrease the need for levodopa.35
DEVELOPMENT OF (− )-1-PHENYL-2-PROPYLAMINOPENTANE
Knoll developed (− )-1-phenyl-2-propylaminopentane, a DEP
analog, which is as equally active with DEP in enhancing the
activity of the catecholaminergic brain engine, but it is devoid of
MAOI property. This study furnished primary evidence that the
main effect of DEP, the specific stimulation of the catecholami-
nergic brain engine, is unrelated to MAO inhibition.31
EVIDENCE THAT DEP TREATMENT PREVENTS AGING-RELATED
PIGMENT CHANGES IN THE SUBSTANTIA NIGRA OF RATS
As neuromelanin is a marker of aging, Knoll and his coworkers
developed a procedure for measuring the number, total area, area
of one granule and density features of melanin granules in neural
cells of the substantia nigra in groups of 3-month-old and 3 years
old male rats. The majority of the neural cells in young rats
contained numerous, small-sized neuromelanin granules, whereas
in the majority of neural cells of old rats, a smaller number of
large-sized granules were detected. DEP treatment completely
prevented aging-related pigment changes.36
EVIDENCE THAT MULTIPLE, SMALL DOSE ADMINISTRATION
OF DEP, WHICH LEAVES MAO-B ACTIVITY UNCHANGED, KEEPS
CATECHOLAMINERGIC NEURONS ON A SIGNIFICANTLY
HIGHER ACTIVITY LEVEL
Rats of both sexes were injected subcutaneously, daily for 21 days,
with 0.1 ml per 100 g saline or with one of the following doses
of DEP: 0.01, 0.025, 0.1 and 0.25 mg kg−1. On brain samples
removed 24 h after the last injection, the amount of biogenic
amines released from the tissue within 20 min was measured:
dopamine from the striatum, substantia nigra and tuberculum
olfactorium; norepinephrine from the locus coeruleus; and
serotonin from the raphe. Compared with the saline-treated rats,
3-week daily treatment even with the lowest dose of DEP
(0.01 mg kg− 1) kept the catecholaminergic neurons working on
a significantly higher activity level.37 These experiments revealed
to Knoll the existence of a key important mechanism, the
enhancer regulation, in the mammalian brain. A new period of
DEP research began with this concept.
CHARACTERISTIC CHANGES IN THE ENHANCER REGULATION
OF THE CATECHOLAMINERGIC AND SEROTONERGIC NEURONS
IN THE DEVELOPMENTAL VERSUS POST-DEVELOPMENTAL
PHASES OF LIFE
In the rat, the interval from weaning (third week of life) until the
end of the second month of age is the decisive developmental
period; the animal acquires crucial abilities for survival and
maintenance of the species. On the basis of the observation that
2-month-old starved rats are significantly more active than their
4-month-old peers, Knoll’s lab checked their dopaminergic,
noradrenergic and serotonergic activities in the brain before
weaning (in 2-week-old rats), during the crucial developmental
phase, from weaning to sexual maturity (in 4- and 8-week-old rats)
and in the early post-developmental phase of life (in 16- and 32-
week-old rats). As an indicator of the basic activity of catechola-
minergic and serotonergic neurons in the brain, Knoll and
his coworkers measured the amount of dopamine released from
the striatum, substantia nigra and tuberculum olfactorium;
norepinephrine from the locus coeruleus; and serotonin from
the raphe.
From weaning until the end of the second month of life the
striatal dopaminergic system of rats was significantly more active
than either before or after that period. There was a marked
increase in the amount of dopamine released from the striatum
and tuberculum olfactorium after weaning (4th week), and its
return to the pre-weaning level (2nd week) in sexually mature rats
(32nd week). The amount of norepinephrine released from the
locus coeruleus and the release of serotonin from the raphe in the
resting state showed the same dramatic increase after weaning,
and return to the pre-weaning level in sexually mature rats.38
These findings indicate that safe and effective measures are
needed to maintain the catecholaminergic brain engine at a
higher activity level during the aging period of life.
DEMONSTRATION THAT PEA IS A MIXED ACTING
SYMPATHOMIMETIC
Because of the effects of PEA, it was and has remained common
knowledge that the trace-amine is an indirectly acting sympatho-
mimetic agent which acts via displacement of catecholaminergic
transmitters from their storage sites. The discovery of the
enhancer regulation in the mammalian brain revealed that PEA,
the physiologically important trace-amine in the mammalian brain
known as a classic releaser of catecholamines from their intra-
neuronal pools, is primarily, in low concentrations, a natural CAE
substance, a selective enhancer of the impulse propagation-
mediated release of catecholamines; and only in high concentra-
tions a releaser of catecholamines.39
Amphetamines, the PEA derivatives not metabolized by MAO,
are like PEA, their parent compound, CAE substances, and in
higher concentrations, releasers of catecholamines. The releasing
effect of PEA, and amphetamines concealed their CAE effect. It
was the development of DEP, the first PEA derivative devoid of the
catecholamine releasing property which rendered possible the
discovery of the CAE effect of PEA and amphetamines.40
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DEP IN THE TREATMENT OF AD
The first two studies demonstrating the beneficial effect of DEP in
AD were published in 1987.41,42 A series of clinical studies with
small sample sizes confirmed the usefulness of this drug in the
treatment of the disease.
The rationale and design of the first multicenter study of DEP in
the treatment of AD using novel clinical outcomes were published
in 1997.43 The study concluded that in patients with moderately
severe impairment from AD, treatment with DEP slows the
progression of the disease.
DEP’s value in the treatment of AD was the subject of a
meta-analysis. There was a statistically significant difference at
4–6 weeks for daily activities, which later disappeared at
assessments at 8–17 weeks.44
Beneficial effects of DEP treatment on cognitive dysfunctions of
aged pet dogs and cats are in harmony with clinical experiences
with AD. DEP (Anipryl) was the first agent approved for cognitive
dysfunction syndrome therapy in dogs.45 Up to now, the largest
amount of research on dogs is conducted with DEP studies.
DEVELOPMENT OF BPAP
The discovery that tryptamine is like PEA, a natural enhancer
substance,25 initiated the development of BPAP, a much more
potent enhancer than DEP, which is enhancing the activity of the
catecholaminergic and serotonergic neurons in femto-picomolar
concentrations.46 DEP is basically ineffective on the serotonergic
system.
It was shown in 2002 that a bi-modal, bell-shaped concentration
effect curve is characteristic in the enhancer effect.47 For example:
Tetrabenazine treatment inhibits the acquisition of a conditioned
avoidance response in rats in the shuttle box. Due to its enhancer
effect, DEP is antagonizing the effect of tetrabenazine in the low-
dose range, with a peak at 0.001 mg kg− 1 (‘specific enhancer
effect’), and in the high-dose range with a peak of 0.25 mg kg− 1
(‘non-specific enhancer effect’), which blocks also MAO-B activity
in the brain.40 This shows that in both research and therapy,
0.25 mg kg− 1 DEP has two effects: it selectively blocks MAO-B
activity and exerts its non-specific enhancer effect.
Although there is good reason to believe that the enhancer
effect of DEP is responsible for the observed changes, only
experiments with BPAP could clarify the role of the enhancer
effect of DEP in the recited data. BPAP is much more potent than
DEP in antagonizing the tetrabenazine-induced learning deficit in
the shuttle box: 0.0001 mg kg− 1 is the peak dose with the specific
enhancer effect, and 0.05 mg kg− 1 is the peak dose with the non-
specific enhancer effect.40
SEX HORMONES (ESTRONE AND TESTOSTERONE) TERMINATE
THE SIGNIFICANTLY ENHANCED ACTIVITY OF THE
CATECHOLAMINERGIC AND SEROTONERGIC NEURONS IN THE
BRAIN, CHARACTERISTIC TO THE POST-WEANING PERIOD
As rats have a significantly more pronounced enhancer regulation
working in the catecholaminergic and serotonergic neurons from
the discontinuation of breast feeding until the appearance of
sexual hormones, the increased enhancer regulation between
weaning and sexual maturity is obviously responsible for the
exuberant physical strength and mental vigor in the uphill period
of life. It is reasonable that sex hormones have a key role in
terminating the developmental phase of life. The regulation of sex
hormones starts working in rats with full capacity only at the end
of their 2nd month of age. This rapid decrease in catecholamines
and serotonin from selected discrete brain regions appeared
synchronously with the completion of sexual maturity. A careful
analysis revealed that estrone and testosterone, but not proges-
terone dampens the enhancer regulation in the catecholaminergic
and serotonergic brain stem neurons, and this is the mechanism
which terminates developmental longevity as well.48
According to the Knoll concept, to keep the catecholaminergic
brain engine, from the beginning of the downhill period of life, via
the administration of a small daily dose of a CAE substance
(presently selegiline is the only available drug) on a higher activity
level, thus to fight against the physiological aging-related, slow
decay of the catecholaminergic system, is a suitable prophylactic
anti-aging measure.40,49–52
Knoll has persistently argued, why the discovery of the
enhancer sensitivity of the catecholaminergic and serotonergic
neurons glimmer just the peak of the iceberg.52 Even the first
developed synthetic enhancers, DEP and BPAP, are not identical in
their molecular mechanism.52,53 Thus, the various forms of natural
enhancers capable to increase the excitability of specifically
sensitive neurons to a maximum level seem to represent a widely
distributed basic mechanism in the mammalian brain. As we have
with the aid of DEP and BPAP a fair chance to rapidly recognize
unknown enhancer regulations in the mammalian brain, and
studies in progress that firmly support this view,40 this new line of
brain research is indeed of great promise.
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